| abstract |
The invention discloses a pyridine-substituted chalcone compound having the structure shown in general formula I or a pharmaceutically acceptable salt thereof, and also discloses a preparation method and application of the above compound or a pharmaceutically acceptable salt thereof. The compounds of the present invention or their pharmaceutically acceptable salts have few side effects, strong water solubility, and are not easy to develop drug resistance, can effectively inhibit the aggregation of tubulin, have strong antitumor activity in vitro and in vivo, and have better metabolism. For stability, the prospect of druggability is good. The present invention also includes the combined use of pyridine substituted chalcone compounds or their pharmaceutically acceptable salts and TACC3 inhibitors to effectively inhibit the activity of tumor cells resistant to tubulin. in, . |